Earnings

Oncolytics Biotech (ONCY) Stock Rating Reiterated at Buy

Published on 5/26/2026

#ONCY#earnings#H.C.Wainwright#buy#stock rating
Oncolytics Biotech (ONCY) Stock Rating Reiterated at Buy

AI Summary

Summarized by AI from the source below

H.C. Wainwright has reiterated its buy rating for Oncolytics Biotech (ONCY). The firm stated that they continue to see potential in the company's product pipeline. This rating is expected to influence investor sentiment positively. Oncolytics Biotech is actively involved in the development of therapies for cancer, which could impact future market performance based on clinical results.

Share:
Source: Read original article (opens in new tab)

Get the free market brief

Top stories and analysis, summarized. No spam, unsubscribe anytime.

Related News

Delta (DAL) Forecasts Q3 Earnings of $2.00 to $2.50 Per Share
Earnings

Delta (DAL) Forecasts Q3 Earnings of $2.00 to $2.50 Per Share

Jul 10

Niagen Bioscience Stock Rating Reiterated by Canaccord Amid Drug Launch
Earnings

Niagen Bioscience Stock Rating Reiterated by Canaccord Amid Drug Launch

Jul 10

Nurix (NRIX) Stock Price Target Raised to $34 by H.C. Wainwright
Earnings

Nurix (NRIX) Stock Price Target Raised to $34 by H.C. Wainwright

Jul 10

PDF Solutions (PDFS) Stock Target Raised on Growth Outlook
Earnings

PDF Solutions (PDFS) Stock Target Raised on Growth Outlook

Jul 10